Hisun Pharmaceutical Exports Fluvastatin To Europe
This article was originally published in PharmAsia News
Hisun Pharmaceutical shipped 900,000 fluvastatin capsules to Europe in November. It is the first China enterprise to cooperate with an overseas partner to enter the EU under its branded pharmaceutical formulation. Hisun collaborates with a German drug manufacturer to apply for European pharmaceutical certifications for its fluvastatin formulation and received approval in August. Even though the fluvastatin export will not contribute substantially to the firm's profit in the short term, it paves the way for Hisun's strategic shift from the production of active pharmaceutical ingredients to higher value-added co-development of APIs and formulations. (Click here for more - Chinese language)
You may also be interested in...
The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Appropriators’ FDA FY 2021 budget includes amendment to expand its mandatory recall authority introduced by chairman of subcommittee with oversight of agency’s budget, Rep. Sanford Bishop. He said the agency should be able to force drug product recalls as it already can for vaccines, medical devices and products containing ingredients also scheduled as controlled substances.